154 related articles for article (PubMed ID: 20010902)
1. Pancreatic steatosis: harbinger of type 2 diabetes in obese rodents.
Lee Y; Lingvay I; Szczepaniak LS; Ravazzola M; Orci L; Unger RH
Int J Obes (Lond); 2010 Feb; 34(2):396-400. PubMed ID: 20010902
[TBL] [Abstract][Full Text] [Related]
2. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
Gastaldelli A; Cusi K; Pettiti M; Hardies J; Miyazaki Y; Berria R; Buzzigoli E; Sironi AM; Cersosimo E; Ferrannini E; Defronzo RA
Gastroenterology; 2007 Aug; 133(2):496-506. PubMed ID: 17681171
[TBL] [Abstract][Full Text] [Related]
3. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
4. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic fat accumulation, fibrosis, and acinar cell injury in the Zucker diabetic fatty rat fed a chronic high-fat diet.
Matsuda A; Makino N; Tozawa T; Shirahata N; Honda T; Ikeda Y; Sato H; Ito M; Kakizaki Y; Akamatsu M; Ueno Y; Kawata S
Pancreas; 2014 Jul; 43(5):735-43. PubMed ID: 24717823
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of the KATP channel subunit, Kir6.2, is associated with decreased expression of neuropeptide Y and agouti-related protein in the hypothalami of Zucker diabetic fatty rats.
Gyte A; Pritchard LE; Jones HB; Brennand JC; White A
J Neuroendocrinol; 2007 Dec; 19(12):941-51. PubMed ID: 18001323
[TBL] [Abstract][Full Text] [Related]
7. Effect of partial pancreatectomy on beta-cell mass in the remnant pancreas of Wistar fatty rats.
Ogino T; Zhu M; Murakami T; Kuwajima M; Shima K
J Med Invest; 1998 Aug; 45(1-4):103-10. PubMed ID: 9864970
[TBL] [Abstract][Full Text] [Related]
8. A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
Schrijvers BF; Flyvbjerg A; Tilton RG; Lameire NH; De Vriese AS
Nephrol Dial Transplant; 2006 Feb; 21(2):324-9. PubMed ID: 16249198
[TBL] [Abstract][Full Text] [Related]
9. Molecular and morphometric description of adipose tissue during weight changes: a quantitative tool for assessment of tissue texture.
Pagano C; Calcagno A; Giacomelli L; Poletti A; Macchi V; Vettor R; De Caro R; Federspil G
Int J Mol Med; 2004 Nov; 14(5):897-902. PubMed ID: 15492863
[TBL] [Abstract][Full Text] [Related]
10. Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure.
Goh TT; Mason TM; Gupta N; So A; Lam TK; Lam L; Lewis GF; Mari A; Giacca A
Am J Physiol Endocrinol Metab; 2007 Feb; 292(2):E549-60. PubMed ID: 17003242
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance in the Zucker diabetic fatty rat: a metabolic characterisation of obese and lean phenotypes.
Leonard BL; Watson RN; Loomes KM; Phillips AR; Cooper GJ
Acta Diabetol; 2005 Dec; 42(4):162-70. PubMed ID: 16382303
[TBL] [Abstract][Full Text] [Related]
12. Regional fat pad growth and cellularity in obese zucker rats: modulation by caloric restriction.
Hausman DB; Fine JB; Tagra K; Fleming SS; Martin RJ; DiGirolamo M
Obes Res; 2003 May; 11(5):674-82. PubMed ID: 12740458
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats.
van Poelje PD; Potter SC; Chandramouli VC; Landau BR; Dang Q; Erion MD
Diabetes; 2006 Jun; 55(6):1747-54. PubMed ID: 16731838
[TBL] [Abstract][Full Text] [Related]
14. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM.
Lee Y; Hirose H; Zhou YT; Esser V; McGarry JD; Unger RH
Diabetes; 1997 Mar; 46(3):408-13. PubMed ID: 9032096
[TBL] [Abstract][Full Text] [Related]
15. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study.
McGavock JM; Lingvay I; Zib I; Tillery T; Salas N; Unger R; Levine BD; Raskin P; Victor RG; Szczepaniak LS
Circulation; 2007 Sep; 116(10):1170-5. PubMed ID: 17698735
[TBL] [Abstract][Full Text] [Related]
16. Changes in the islets of langerhans in the obese Zucker rat.
Larsson LI; Boder GB; Shaw WN
Lab Invest; 1977 Jun; 36(6):593-8. PubMed ID: 325294
[TBL] [Abstract][Full Text] [Related]
17. Metabolic implications of dietary trans-fatty acids.
Dorfman SE; Laurent D; Gounarides JS; Li X; Mullarkey TL; Rocheford EC; Sari-Sarraf F; Hirsch EA; Hughes TE; Commerford SR
Obesity (Silver Spring); 2009 Jun; 17(6):1200-7. PubMed ID: 19584878
[TBL] [Abstract][Full Text] [Related]
18. Acceleration of the development of diabetes in obese diabetic (db/db) mice by nicotinamide: a comparison with its antidiabetic effects in non-obese diabetic mice.
Piercy V; Toseland CD; Turner NC
Metabolism; 2000 Dec; 49(12):1548-54. PubMed ID: 11145115
[TBL] [Abstract][Full Text] [Related]
19. Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia.
Smith AC; Mullen KL; Junkin KA; Nickerson J; Chabowski A; Bonen A; Dyck DJ
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E172-81. PubMed ID: 17374701
[TBL] [Abstract][Full Text] [Related]
20. Use of proton spectroscopy for detection of homozygous fatty ZDF-drt rats before weaning.
Stein DT; Babcock EE; Malloy CR; McGarry JD
Int J Obes Relat Metab Disord; 1995 Nov; 19(11):804-10. PubMed ID: 8589782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
